Apollomics (APLM) Other Accumulated Expenses (2022 - 2025)

Apollomics (APLM) reported Other Accumulated Expenses of $6.1 million for Q4 2025, down 52.23% quarter-over-quarter from $12.8 million in Q2 2023.

Apollomics (APLM) Other Accumulated Expenses (2022 - 2025) Analysis & Trends

Apollomics (APLM) has 3 years of Other Accumulated Expenses data on file, last reported at $6.1 million in Q4 2025.

  • Other Accumulated Expenses for Q4 2025 came in at $6.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.1 million (changed N/A YoY), and the FY2025 annual result was $6.1 million, changed N/A from the prior year.
  • Other Accumulated Expenses eased to $6.1 million in Q4 2025 per APLM's latest filing, from $12.8 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $12.8 million in Q2 2023 and troughed at $6.1 million in Q4 2025.
  • A 3-year average of $10.2 million and a median of $11.7 million in 2022 frame the typical range for Other Accumulated Expenses.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn -
7 Psyence Biomedical 241.78 Bn 241.78 Bn -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn
9 Abivax 94.26 Bn 94.26 Bn -
10 Apollomics 294.00 Mn 294.00 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 6.12 Mn
Jun 30, 2023 12.80 Mn
Dec 31, 2022 11.68 Mn